12LOX Cancer Research Results

12LOX, 12‐lipoxygenase: Click to Expand ⟱
Source:
Type:
12‐lipoxygenase (commonly abbreviated as 12-LOX)
12-LOX (12-lipoxygenase) is an enzyme that plays a role in the metabolism of polyunsaturated fatty acids—in particular, converting arachidonic acid into bioactive lipid mediators such as 12-hydroxyeicosatetraenoic acid (12-HETE).
-12-LOX is implicated in several mechanisms that can promote cancer, including supporting inflammation, cell survival, angiogenesis, and metastasis.
High 12-LOX expression in several cancer types is generally correlated with more aggressive disease and poorer clinical outcomes. However, the prognostic significance may vary between cancers and patient populations. Ongoing research is aiming to clarify:
– Whether 12-LOX can be reliably used as a prognostic biomarker
– And whether targeting 12-LOX might serve as a therapeutic strategy in cancer management.
– Increased Levels of 12-LOX in ESCC Patients with Poor Prognosis
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
2479- Ba,    Baicalein Overcomes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells
- in-vitro, HCC, SW480 - in-vitro, Pca, PC3
12LOX↓, DR5↑, CHOP↑, ROS↑, *ROS∅, selectivity↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,  

Cell Death ⓘ

DR5↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,  

Drug Metabolism & Resistance ⓘ

selectivity↑, 1,  
Total Targets: 5

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS∅, 1,  
Total Targets: 1

Scientific Paper Hit Count for: 12LOX, 12‐lipoxygenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:1126  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page